Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-18. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Storyteller === Conway styles himself "Furrydom's Storyteller", making annual appearances at Anthrocon in what has come to be known as Uncle Kage's Story Hour. The entertainment typically consists of four or five extended personal anecdotes. His stage name resulted from his first storytelling experience at ConFurence in 1994, and derives from his fandom name Kagemushi Goro (Shadow Bug Goro), a reference to Kagemusha. Conway is regularly invited to tell his stories at other fan conventions, including I-CON, Eurofurence, ConClave, and Camp Feral!. Gross sales from recordings of his Story Hours were over US$2600 in 2004; no profit was realized, as the intention was to increase membership and awareness of Anthrocon.
=== COVID-19 === At the start of the COVID-19 pandemic, some doctors observed that anecdotally some hospitalized patients in China may have had better outcomes on famotidine than other patients who were not taking famotidine. This led to hypotheses about use of famotidine in treatment of COVID-19. Famotidine was considered a possible treatment for COVID-19 due to its potential anti-inflammatory effects. It was thought that famotidine could modify lung inflammation caused by coronaviruses. However, studies have shown that famotidine is not effective in reducing mortality or improving recovery in COVID-19 patients. Famotidine primarily works by blocking the effects of histamine and has some potential mechanisms of action that may contribute to its anti-inflammatory properties, including the inhibition of the production of certain pro-inflammatory cytokines such as TNF-alpha and IL-6. Another hypothesis was that famotidine might activate the vagus nerve inflammatory reflex to attenuate cytokine storm. Yet another hypothesis was that famotidine can reduce the activation of mast cells and the subsequent release of inflammatory mediators, therefore acting as a mast cell stabilizer. However, while famotidine may have some anti-inflammatory effects, there is currently insufficient evidence to support its use for treating inflammation associated with COVID-19. Therefore, it is not recommended for this purpose.
== Education == Coatsworth was educated at Wesley College in South Perth which he attended between 1985 and 1995. At Wesley he was awarded the Philip Goatcher Scholarship for Years 11 and 12. He also spent five years on the school's debating team which he believes helped to prepare him for communicating with the public. He attended the University of Western Australia. He graduated with Honours in 2001. In 2022 the university awarded him an Honorary Doctorate for services to medicine. He has a Masters in International Public Health from the University of Sydney.
== G == GABA (Gamma-Aminobutyric Acid) The primary inhibitory neurotransmitter in the central nervous system. It reduces neuronal excitability and is involved in sleep, anxiety, and motor control. Gag reflex A protective reflex that prevents choking, triggered by stimulation of the back of the throat. It involves cranial nerves IX and X and is used to assess brainstem function. Ganglion A cluster of neuronal cell bodies located outside the central nervous system. Examples include the dorsal root ganglia and autonomic ganglia. Gap junction A direct electrical connection between adjacent neurons or glial cells formed by connexin proteins. Gap junctions allow ions and small molecules to pass rapidly between cells. Gene knockout A genetic technique used to inactivate or "knock out" a specific gene in an organism to study its function. Widely used in neuroscience to explore gene roles in brain development and behavior. Genetic predisposition An increased likelihood of developing a particular disease based on an individual's genetic makeup. In neuroscience, it is relevant to conditions like schizophrenia and Alzheimer's disease. Geniculate body A relay structure in the thalamus. The lateral geniculate body is involved in visual processing; the medial geniculate body is involved in auditory processing. Gephyrin A scaffolding protein that anchors inhibitory neurotransmitter receptors (GABA and glycine) at postsynaptic sites. Essential for synapse formation and stability. Glia Non-neuronal cells in the nervous system that support, nourish, and protect neurons.
West Berlin was under the sovereignty of the Western Allies and neither a Western German state nor part of one. However, it was in many ways integrated with West Germany under a special status. A new delimitation of the federal territory has been discussed since the Federal Republic was founded in 1949 and even before. Committees and expert commissions advocated a reduction of the number of states; academics (Werner Rutz, Meinhard Miegel, Adrian Ottnad, etc.) and politicians (Walter Döring, Hans Apel, and others) made proposals – some of them far-reaching – for redrawing boundaries but hardly anything came of these public discussions. Territorial reform is sometimes propagated by the richer states as a means to avoid or reduce fiscal transfers.
Sources: en.wikipedia.org
In Pakistan, all sexual activity outside of marriage is illegal. The punishment for sex outside marriage (zina) ranges from up to five years' imprisonment for minors to 100 lashes for unmarried adults and stoning to death for married adults, depending on marital status, age, sanity, and whether strict evidentiary requirements for a hadd punishment—such as four adult male Muslim witnesses or a confession—are met; however, no one has been stoned to death under the law to date. Male homosexuality is illegal in Pakistan and is punishable by up to ten years in prison, corporal punishment such as whipping, and, under Islamic law since 1990, potentially even stoning. Honour killings, locally referred to as karo-kari in parts of Pakistan, involve the killing of women and, less frequently, men by family or community members over alleged extramarital relationships or perceived violations of honour. Human rights organisations report that hundreds of women are killed each year, with many cases unreported. Pakistan also has a high number of reported acid attacks, with about 200 incidents annually as of 2023, most victims being women. According to Masarrat Misbah, founder of the Depilex Smileagain Foundation, women have been targeted for rejecting marriage proposals, giving birth to daughters instead of sons, or insufficient dowry. The 2011 Acid and Burn Crime Bill criminalised acid attacks, making them punishable by lengthy imprisonment and fines. In parts of Pakistan, girls are given in marriage to settle disputes or crimes between families in a customary practice called Vani.
Finasteride/latanoprost/minoxidil (developmental code name TH-07 or TH07) is a topical combination drug which is under development for the treatment of alopecia (hair loss). It is specifically a combination of finasteride (Propecia) (0.1%), a 5α-reductase inhibitor (5α-RI); latanoprost (Xalatan) (0.03%), a prostaglandin F2α analogue and prostaglandin F receptor agonist; and minoxidil (Rogaine) (5%), a KATP potassium channel opener. All three of these drugs have individually been shown to stimulate hair growth in the setting of alopecia, and both finasteride and minoxidil are approved and widely used for treatment of alopecia. Finasteride/latanoprost/minoxidil is under development by Triple Hair. As of December 2023, the drug is in phase 2 clinical trials.
To calculate the actual location over the ground, the altitude also had to be measured (see below) and then calculated using simple trigonometry. A variety of calculators and aids were used to help in this calculation step. As the plotter worked, the targets would be updated over time, causing a series of marks, or plots, to appear that indicated the targets' direction of motion, or track. Track-tellers standing around the map would then relay this information via telephone to the filter room at RAF Bentley Priory, where a dedicated telephone operator relayed that information to plotters on a much larger map. In this way the reports from multiple stations were re-created into a single overall view. Due to differences in reception patterns between stations, as well as differences in received signals from different directions even at a single station, the reported locations varied from the target's real location by a varying amount. The same target as reported from two different stations could appear in very different locations on the filter room's plot. It was the job of the filter room to recognize these were actually the same plot, and re-combine them into a single track. From then on each track was identified by a number, which would be used for all future communications. When first reported the tracks were given an "X" prefix, and then "H" for Hostile or "F" for friendly once identified. This data was then sent down the telephone network to the Group and Section headquarters where the plots were again re-created for local control over the fighters.
There was also honorary membership bestowed on those who had made unusual services to the Catholic faith, social or economic science, the arts, education, French culture generally, or to any other ideal of the association. 1967 membership 30,424; 1979 membership 26,000. Absorbed Foresters Franco Americains in 1939. The ACA went into rehabilitation in 2008 and later was liquidated. Most of its insurance policies were assumed by the Royal Arcanum.
Septal mucosal flap The septal mucosal tissue flap is the indicated technique for correcting defects of the distal half of the nose, and for correcting almost every type of large defect of the mucosal lining of the nose. The septal mucosal tissue flap, which is an anteriorly based pedicle-graft supplied with blood by the septal branch of the superior labial artery. To perform such a nasal correction, the entire septal mucoperichondrium can be harvested.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.